This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatmentTEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic ...

Group 1 - Jiangfeng Electronics plans to raise no more than 1.95 billion yuan for the production of 12,300 ultra-pure metal sputtering targets for integrated circuits and other projects [1] - Northern Rare Earth has adjusted the trading price of rare earth concentrates to 19,109 yuan per ton for Q3 2025, reflecting a 1.5% increase from the previous price [2] - Baogang Co. also plans to adjust the trading price of rare earth concentrates to 19,109 yuan per ton for Q3 2025, indicating a 1.5% increase [3] Group 2 - Shijia Photon intends to acquire 82.3810% equity of Fokexima through a combination of share issuance and cash payment, aiming to enhance its production capabilities and reduce costs [4] - Yiling Pharmaceutical's application for the registration of Banxia Baizhu Tianma granules has been accepted, marking its first classic prescription product [5] - Liangpinpuzi's controlling shareholder is planning a change of control, leading to a temporary suspension of its stock [6] Group 3 - Qin'an Co. plans to acquire 99% equity of Yigao Optoelectronics through share issuance and cash payment, with stock resuming trading [7] - Goldwind Technology's shareholder, Harmony Health, intends to reduce its stake by up to 1% within three months [8] Group 4 - Tianbao Infrastructure expects a net profit of 90 million to 130 million yuan for the first half of the year, representing a year-on-year increase of 1581.80% to 2329.27% [10] - Guosheng Jinkong anticipates a net profit of 150 million to 220 million yuan for the first half of the year, a year-on-year growth of 236.85% to 394.05% [10] - China Shipbuilding expects a net profit of 2.8 billion to 3.1 billion yuan for the first half of the year, reflecting a year-on-year increase of 98.25% to 119.49% [10]

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representa ...

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, according to data from Benzinga Pro. The company' sales came in at $257.10 million versus estimates of $232.87 million.Methode Electronics sh ...

BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results” on Se ...

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURH ...

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI. “Molluscum impacts millions of people in the U.S., particularly children. ...

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial ...